4//SEC Filing
Luehrs Bruce 4
Accession 0001179110-18-007044
CIK 0001651561other
Filed
May 16, 8:00 PM ET
Accepted
May 17, 5:18 PM ET
Size
17.1 KB
Accession
0001179110-18-007044
Insider Transaction Report
Form 4
Luehrs Bruce
Director
Transactions
- Sale
Common Stock
2018-05-17$50.41/sh−7,786$392,492→ 85,842 total(indirect: See footnotes) - Sale
Common Stock
2018-05-16$47.87/sh−1,947$93,203→ 116,326 total(indirect: See footnotes) - Sale
Common Stock
2018-05-17$48.88/sh−100$4,888→ 97,828 total(indirect: See footnotes) - Sale
Common Stock
2018-05-16$48.61/sh−16,950$823,940→ 99,376 total(indirect: See footnotes) - Sale
Common Stock
2018-05-16$49.03/sh−1,448$70,995→ 97,928 total(indirect: See footnotes) - Sale
Common Stock
2018-05-17$49.74/sh−4,200$208,908→ 93,628 total(indirect: See footnotes)
Holdings
- 8,161
Common Stock
Footnotes (8)
- [F1]Includes a restricted stock award of 3,710 shares of the Company's common stock received by Bruce Luehrs on September 28, 2016, of which shares 1,236 are vested and 2,474 are unvested. Also includes a restricted stock award of 1,855 shares of the Company's common stock received by Bruce Luehrs on September 28, 2016, all of which are vested. Also includes a restricted stock award of 2,596 shares of the Company's common stock received by Bruce Luehrs on June 16, 2017. Such common stock vests in full on the earlier of the next annual shareholder meeting or the one year anniversary of the date of grant.
- [F2]These securities are held by Emerald Stage2Ventures, L.P. Stage2 Capital Ventures Associates, L.P. is the general partner of Emerald Stage2 Ventures, L.P. and Stage2 Capital Associates G.P., LLC is the general partner of Stage2 Capital Ventures Associates, L.P. Bruce Luehrs, who serves as a director of the Issuer, is an officer of Stage2 Capital Associates G.P., LLC.
- [F3]The Reporting Person disclaims beneficial ownership (as defined in Rule 16a-1(a)(2)) of the securities reported herein (except to the extent of his pecuniary interest in such securities), and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $47.76 to $47.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (4) to this Form 4.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $48.00 to $48.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (5) to this Form 4.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $49.00 to $49.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (6) to this Form 4.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $49.00 to $49.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (7) to this Form 4.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $50.01 to $50.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (8) to this Form 4.
Documents
Issuer
Tabula Rasa HealthCare, Inc.
CIK 0001651561
Entity typeother
Related Parties
1- filerCIK 0001352929
Filing Metadata
- Form type
- 4
- Filed
- May 16, 8:00 PM ET
- Accepted
- May 17, 5:18 PM ET
- Size
- 17.1 KB